CF
NBIX icon

Cantor Fitzgerald’s Neurocrine Biosciences NBIX Stock Holding History

Cantor Fitzgerald’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-94,584
Closed -$10.6M – 442
2023
Q3 		$10.6M Sell
94,584
-750
-0.8% -$79K 0.28% 123
2023
Q2 		$8.99M Sell
95,334
-120
-0.1% -$11.7K 0.21% 157
2023
Q1 		$9.66M Sell
95,454
-4,651
-5% -$484K 0.21% 169
2022
Q4 		$12M Buy
100,105
+6,825
+7% +$799K 0.26% 136
2022
Q3 		$9.91M Buy
+93,280
New +$9.46M 0.22% 150

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cantor Fitzgerald's NBIX Position: Q4 2023 in Review

Cantor Fitzgerald sold out of Neurocrine Biosciences (NBIX) in Q4 2023, closing a stake of 94,584 shares — an estimated $10.6M sold.

Cantor Fitzgerald first reported a position in NBIX in Q3 2022 and held it in 5 quarters. The position peaked at $12M in Q4 2022. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

  • Cantor Fitzgerald reported no remaining Neurocrine Biosciences position as of Q4 2023 after selling out during the quarter.
  • Cantor Fitzgerald sold 94,584 Neurocrine Biosciences shares in Q4 2023, an estimated $10.6M.
  • Cantor Fitzgerald first reported a position in Neurocrine Biosciences in Q3 2022 and held it in 5 quarters.
  • Cantor Fitzgerald's Neurocrine Biosciences position peaked at $12M in Q4 2022.
  • 554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.